Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice way of looking at that
BOOYA GNTA!
try GNTA,,,its only .0054
only 7 billion left...hmmmm then it might go to a penny
lol...realistically I hope this company gets bought out and we all make a ton of money! good luck to all!
could you put that list up again Rasta...it was awful helpful
having gone thru chemotherapy and dealing with needles constantly for 7 months and a g-tube inserted into my stomache I sincerely pray that our country finds the cure for cancer
I survived cancer and it was the toughest thing I ever did, that is why I am investing in this company. go GNTA!
http://activerain.com/blogsview/256452/How-I-Survived-Cancer
thats huge news for FRE
sign of a great company isnt it?
PRGN is hot if you like DRYS
got this from the Yahoo board...Stock100.com has the following price outlook for CTIC next week:
01/05/09: 0.16
01/06/09: 0.19
01/07/09: 0.23
01/08/09: 0.26
01/09/09: 0.26
Hold on everybody for a great week next week!
whoever missed buying Last friday will definately be sorry if they dont buy tommorow! IMHO
tell that to the person that just bought 210,000 shares at .132
someone is buying...I think there are a lot of sells disguised as buys - buy your CTIC tickets for the upcoming ride....you dont wanna miss this one.
FRE:Freddie Mac
News and Ginnie Mae will start having their backed mortgage securities bought in early January by the Federal Reserve. The Fed said it "has selected private investment managers to act as its agents in implementing the program," which is "separate and distinct from the U.S. Treasury's program." The purchases will be financed through the creation of additional bank reserves, the Fed said
holding CTIC & KERX - both jamming today!
I call it "The Obama Effect"
CTIC starting to rise ...watch it fence sitters~!
sounds GREAT SA! You Da best Chart Specialist on the net! see you in the Room
looks like I might have picked up my final batch at .13
NOW TO DA MOON ALICE!
it will move on supply and demand. period EOM
Latest institution that bought CTIC on 12/23/08
California Public Employees Retirement System Institution 0.00 % 2008-12-23 11,980 $1,557 $0 0.00 % New Holding 11,980 100.00 %
good to see the instituitons buying click here to see the others: http://www.mffais.com/ctic.html
CTIC - The best Xmas present one could ask for!
in at 2.17
CTIC - looking for news - Then KABOOM!
my favorite stock!
cant believe Dallas lost the last game in Texas stadium...sad....
SA - am playing CTIC and KERX ... you have any stocks you are hot on?
artmaniac
having had throat cancer in the last year, I can appreciate what CTIC is doing....
The part of CTIC that excites me is this: The Notes will automatically convert if, at any time after December 5, 2009 and prior to maturity, the closing price of the Common Stock has exceeded $0.274 for at least 20 trading days within any 30 consecutive trading day period, subject to certain conditions (a “ Triggering Event ”).
wonder what the triggering event will be????
read more:
On December 4, 2008, Cell Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with BAM Opportunity Fund LP (the “ Investor ”). Pursuant to the Purchase Agreement, on December 5, 2008 the Company issued to the Investor $32,651,321 principal amount of the Company’s 10% Convertible Senior Notes due 2011 (the “ Notes ”) for $32,651,321 cash.
Also pursuant to the Purchase Agreement, and also on December 5, 2008, the Company repurchased, for approximately $29.0 million, approximately $30.0 million principal amount of the Company’s 15% Convertible Senior Notes due 2011 issued in June 2008 to the Investor, Series B 18.33% Convertible Senior Notes due 2011 issued in August 2008 to the Investor and 9.66% Convertible Senior Notes due 2011 issued in October 2008 to the Investor (the “ Repurchased Notes ”) and warrants to purchase approximately 5.15 million shares of common stock issued in 2007 and 2008 to the Investor. The Company used approximately $16.4 million of the Notes issuance proceeds as a portion of the approximately $29.0 million repurchase price for the Repurchased Notes and warrants and used funds released to it from the escrow account established to pay the make-whole and interest payments on the Repurchased Notes to pay the remaining approximately $12.6 million of the repurchase price.
The Notes were issued pursuant to an Indenture dated December 5, 2008 between the Company and U.S. Bank National Association as trustee (the “ Indenture ”).
The Notes will bear an annual interest rate of 10% and are convertible into Common Stock at the option of the Holder at a conversion price of $0.137 per share. Accordingly, the Notes are convertible into 238,330,810 shares of Common Stock.
The Notes will automatically convert if, at any time after December 5, 2009 and prior to maturity, the closing price of the Common Stock has exceeded $0.274 for at least 20 trading days within any 30 consecutive trading day period, subject to certain conditions (a “ Triggering Event ”). The amount of Notes that shall automatically convert on a Triggering Event may be limited, depending upon the volume weighted average price of the Common Stock at that time. Once a Triggering Event has occurred, a new 30 trading day period for which an automatic conversion may be triggered shall commence.
Upon the optional or automatic conversion of the Notes, the Company shall be required to pay a make-whole amount to the holders of the Notes so converted equal to $300 per $1,000 principal amount of the converted Notes less any interest paid on such Notes before conversion (a “ Make-Whole Payment ”). The Company has placed an amount adequate to pay the Make-Whole Payments on all outstanding Notes in escrow to be held for a period of one year. At the end of one year, all funds remaining in escrow will be released to the Company.
In the case of an event of default the Notes can be accelerated.
In the event of certain changes in control, holders of the Notes may require the Company to repurchase their Notes at a repurchase price equal to 100% of the aggregate principal amount of such holders’ outstanding notes at the time of such repurchase, together with interest accrued to the repurchase date.
If not converted or repurchased prior to maturity, the Notes mature on December 5, 2011.
The Notes are the Company’s unsecured obligations and are not subordinated to any of its present or future unsecured obligations. The Company has also agreed to certain restrictions on its incurrence of future secured indebtedness.
--------------------------------------------------------------------------------
Under the Purchase Agreement, the Investor agreed to maintain ownership, at all times until no more than $1.635 million of the Notes remains outstanding, of a common stock long position representing at least 9.0% of the total number of then-outstanding shares of common stock of the Company.
In addition, under the Purchase Agreement, the Investor also granted the Company a conditional put option right to issue and sell to the Investor an additional $3 million of Series C 10% Convertible Senior Notes of the Company (the “ C Notes ”) if the Company makes a convertible notes repurchase tender offer and receives tenders (which are not withdrawn) of at least $62 million principal amount of convertible notes, or to issue and sell to the Investor an additional $6 million of C Notes if the Company makes a convertible notes repurchase tender offer and receives tenders (which are not withdrawn) of at least $93 million principal amount of convertible notes. The C Notes would have substantially the same terms as the Notes.
The description of the terms and conditions of the Purchase Agreement, the Indenture and the Notes set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Purchase Agreement and the Indenture which are attached hereto as Exhibit 10.1 and 4.1, respectively.
The net proceeds to the Company from the sale of the Notes were $6.5 million (before payment of fees and expenses), after (a) the repurchase of the Repurchased Notes, (b) depositing $9.8 million in escrow for the Make-Whole Payment and (c) receiving approximately $12.6 million from the escrow account established to pay the make-whole and interest payments on the Repurchased Notes.
The offer and sale of the Notes and the shares of Common Stock underlying them, and the offer of the C Notes and the shares of Common Stock underlying them, were covered by Form S-3 shelf registration statements of the Company (File Nos. 333-131533, 333-149982 and 333-153358).
BUY CELL THERAPEUTICS
Zacks isues BUY-Rating
In a recent analytical update on oncology-centric biopharma company Cell Therapeutics, Inc. (CTIC), Zacks senior healthcare analyst Grant Zeng, CFA has issued a Buy rating on the company. We excerpted the following details:
"Cell Therapeutics, Inc. develops, acquires, and commercializes novel treatments for cancer. Recent acquisition of Zevalin should generate revenue for the company and prepare the company for the future launch of other cancer products. Two pipeline products, Xyotax and Pixantrone, account for the late-stage oncology focus. We are optimistic about Cell Therapeutics' future, and believe the shares are attractive at the current level.
"In September 2006, Cell Therapeutics entered into a partnership agreement with Novartis (NVS) for Xyotax. The deal included as much as $270 million registration and sales milestone payment to CTIC and $15 million equity investment. The agreement also provided Novartis the option to develop and commercialize Pixantrone based on agreed terms.
"If Novartis exercises its option on Pixantrone, it would pay CTIC a $7.5 million fee and up to $104 million in registration and sales related milestones. Given the current low stock price, we believe the market is significantly discounting the possibility that Xyotax or Pixantrone receives U.S. Food and Drug Administration (FDA) approval.
"We believe that most of the risks have been factored into the current share price and we would be buyers of the stock given our belief that Xyotax and Pixantrone will be on the market in 2009. In our view, the street is overly pessimistic on the development programs for Xyotax and Pixantrone. We continue to rate the stock a Buy, with a price target of $6."
NO-BRAINERRRRR here imo! BUYING MORE on Monday, didn't know about this Novartis deal! Good Luck everyone, PATIENCE will payoff BIGTIME here imvho. Have a GREAT wknd everyone. MBD
big news GUMZA - CTIC just out with 8-K
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6036860
CTIC - either the lotto or bust - I am in with a nice size position at .13
key word "MAY"
The Company may earn an additional $15 million in product sales milestone payments upon achievement of certain revenue targets.
is there dilution here?
The Notes were issued pursuant to an Indenture dated December 5, 2008 between the Company and U.S. Bank National Association as trustee (the “ Indenture ”).
The Notes will bear an annual interest rate of 10% and are convertible into Common Stock at the option of the Holder at a conversion price of $0.137 per share. Accordingly, the Notes are convertible into 238,330,810 shares of Common Stock.
CTIC just read only a little
The Notes were issued pursuant to an Indenture dated December 5, 2008 between the Company and U.S. Bank National Association as trustee (the “ Indenture ”).
The Notes will bear an annual interest rate of 10% and are convertible into Common Stock at the option of the Holder at a conversion price of $0.137 per share. Accordingly, the Notes are convertible into 238,330,810 shares of Common Stock.
this AM saw a 137,000 share buy into KERX...somebody knows something!
if FDA approval happens for KERX - over a buck could happen quick IMO
watch HUN - train is boarding now
HUN - huge buy! down 50% today! load up
anyone have a bottom prediction?